Kenvue
KVUE
$18.88
-1.51%
Kenvue Inc. is the world's largest pure-play consumer health company, generating over $15 billion in annual revenue from a portfolio of iconic brands including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Spun off from Johnson & Johnson in May 2023, Kenvue operates across self-care, essential health, and skin health/beauty categories, holding leading market positions in many of its segments. The current investor narrative centers on the pending acquisition by Kimberly-Clark, announced in November 2025 and expected to close in the second half of 2026, which has created a unique situation where the stock's value is largely tied to deal completion rather than standalone performance. Additionally, the company has been navigating post-IPO challenges including litigation, competitive pressures, and a recent earnings beat that has sparked some optimism about its operational trajectory.…
KVUE
Kenvue
$18.88
Related headlines
Investment Opinion: Should I buy KVUE Today?
Based on the analysis, KVUE is rated a Hold. The stock offers a 4.8% dividend yield and trades at a forward P/E of 15.44x, which is reasonable, but the acquisition overhang limits upside. The average analyst target of $19.50 is only 1.7% above the current price, indicating limited appreciation potential. The consensus recommendation is 'hold' with a mean rating of 2.79, reflecting cautious optimism.
Sign up to view all
KVUE 12-Month Price Forecast
The AI assessment is neutral, reflecting a balanced risk-reward profile. The stock is fairly valued with limited upside, but the acquisition provides a floor. Key factors include the reasonable forward P/E, stable but modest growth, and the hold rating from analysts. The stance would upgrade to bullish if the acquisition is confirmed with a premium or if revenue growth accelerates above 6%. It would downgrade to bearish if the deal fails or if litigation costs escalate significantly.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Kenvue's 12-month outlook, with a consensus price target around $19.50 and implied upside of +3.3% versus the current price.
Average Target
$19.50
0 analysts
Implied Upside
+3.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$18 - $23
Analyst target range
The target price range spans from a low of $18.00 to a high of $23.00, with the average at $19.50. The low target of $18.00 implies a 6.1% downside from the current price, likely pricing in risks such as litigation, competitive pressures, or a potential breakdown of the Kimberly-Clark acquisition. The high target of $23.00 suggests a 20.0% upside, which would assume successful completion of the acquisition at a favorable price or a significant improvement in standalone fundamentals. The spread between low and high targets is $5.00, or 26% of the average target, indicating moderate uncertainty. The recent ratings actions have been predominantly neutral, with no upgrades in the past six months, and the overall sentiment is cautious, reflecting the stock's limited upside potential given the acquisition overhang.
Bulls vs Bears: KVUE Investment Factors
Kenvue presents a mixed picture: strong fundamentals with stable growth, high margins, and an attractive dividend yield, but offset by acquisition uncertainty, weak relative performance, and valuation concerns. The bull case rests on the stock being undervalued on forward metrics and the potential for the Kimberly-Clark deal to unlock value. The bear case highlights the capped upside, litigation risks, and the stock's underperformance. Currently, the bearish evidence is slightly stronger due to the acquisition overhang and negative momentum, but the downside is limited by the deal floor. The key tension is whether the acquisition completes successfully, which would likely push the stock toward the high target, versus a breakdown that could send it to the low target.
Bullish
- Undervalued on PEG and Forward P/E: KVUE trades at a forward P/E of 15.44x and a PEG ratio of 0.52, implying the stock is undervalued relative to its expected earnings growth. This suggests the market is pricing in limited growth, providing a margin of safety for investors.
- Stable Revenue Growth and Diversified Portfolio: Revenue grew 4.49% YoY in Q1 2026 to $3.909 billion, with consistent low-single-digit growth across quarters. The portfolio spans iconic brands like Tylenol and Listerine, offering defensive characteristics in a consumer staples sector.
- Strong Gross and Operating Margins: Gross margin stands at 58.1% and operating margin at 17.9% (Q1 2026: 21.9%), reflecting efficient cost management and brand pricing power. These margins are typical of high-quality consumer health companies.
- Attractive Dividend Yield with Payout Coverage: The dividend yield is 4.8%, supported by a payout ratio of 107.5% (trailing), which is high but sustainable given strong free cash flow of $1.823 billion TTM. Income investors may find this yield compelling.
Bearish
- Acquisition Overhang Caps Upside: The stock's value is largely tied to the Kimberly-Clark deal, limiting standalone upside. The average analyst target of $19.50 is only 1.7% above the current price, reflecting limited appreciation potential until deal clarity.
- Weak Relative Performance vs. Market: KVUE underperformed the S&P 500 over the past year, with a -6.67% return versus SPY's +18.56%. Relative strength is negative across 1-month (-8.6%) and 6-month (-11.9%), indicating persistent selling pressure.
- High Trailing P/E and Low Growth: The trailing P/E of 22.32x is elevated for a company with only 4.5% revenue growth. This implies the market expects significant earnings acceleration, which may not materialize if growth remains subdued.
- Litigation and Competitive Pressures: Recent news highlights product litigation and analyst downgrades, which could weigh on sentiment. The low analyst target of $18.00 suggests a 6.1% downside risk if these issues escalate.
KVUE Technical Analysis
Kenvue's stock has been in a broad recovery phase over the past year, with the price rising from a 52-week low of $14.02 to a current level of $19.17, representing a 36.7% gain off the bottom. However, the 1-year price change is -6.67%, indicating that the stock is still below its level from a year ago, and it currently sits at 82.6% of its 52-week range (calculated as (19.17-14.02)/(20.82-14.02)). This positioning near the upper end of the range suggests that the stock has regained significant momentum but may be approaching resistance levels, with the 52-week high of $20.82 acting as a key ceiling.
Beta
0.43
0.43x market volatility
Max Drawdown
-36.9%
Largest decline past year
52-Week Range
$14-$21
Price range past year
Annual Return
-8.8%
Cumulative gain past year
| Period | KVUE Return | S&P 500 |
|---|---|---|
| 1m | -1.9% | +2.7% |
| 3m | +9.0% | +1.0% |
| 6m | +3.8% | +12.0% |
| 1y | -8.8% | +18.9% |
| ytd | +9.0% | +12.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
KVUE Fundamental Analysis
Kenvue's revenue trajectory shows modest but steady growth, with the most recent quarter (Q1 2026, ended March 29, 2026) reporting revenue of $3.909 billion, a 4.49% increase year-over-year. This growth is consistent with the prior quarters: Q4 2025 revenue was $3.78 billion, Q3 2025 was $3.764 billion, and Q2 2025 was $3.839 billion, indicating a stable, low-single-digit growth pattern. The company's revenue is diversified across segments, with Self Care contributing $1.699 billion, Essential Health $1.151 billion, and Skin Health and Beauty $1.059 billion in the latest quarter, though segment growth rates are not provided. The growth trajectory, while not explosive, is positive and reflects the defensive nature of the consumer health industry, which should appeal to investors seeking stability.
Quarterly Revenue
$3.9B
2026-03
Revenue YoY Growth
+4.5%
YoY Comparison
Gross Margin
58.9%
Latest Quarter
Free Cash Flow
$1.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is KVUE Overvalued?
For valuation, I selected the P/E ratio as the primary metric because Kenvue is profitable, with trailing EPS of $0.86 (calculated from net income of $474 million and diluted shares of 1.922 billion). The trailing P/E is 22.32x, while the forward P/E is 15.44x, based on estimated EPS of $1.46 for the next fiscal year. The significant gap between trailing and forward P/E (a 30.8% discount) implies that the market expects substantial earnings growth, which is supported by the PEG ratio of 0.52, suggesting the stock is undervalued relative to its growth rate.
PE
22.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 17x~36x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a high payout ratio of 107.5%, meaning dividends exceed net income, which could force a cut if earnings decline. Debt-to-equity of 0.79 and interest expenses of $95 million per quarter (Q1 2026) add leverage risk, especially if rates stay high. The current ratio of 0.96 indicates potential liquidity pressure, though free cash flow of $1.823 billion TTM provides some cushion. Revenue growth is modest at 4.5%, and any deceleration could strain the dividend and valuation.